A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors
Phase 1
Recruiting
- Conditions
- Solid Tumor
- Interventions
- Biological: CLDN6 CAR-TBiological: CLDN6 uRNA-LPX/CLDN6 modRNA-LPX
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- BioNTech Cell & Gene Therapies GmbH
- Target Recruit Count
- 147
- Registration Number
- NCT04503278
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
🇩🇪Charité - Universitätsmedizin Berlin - Campus Benjamin Franklin, Berlin, Germany
🇩🇪Universitätsklinikum Erlangen - Hämatologie & Intrinsische Onkologie - Medizinische Klinik 5, Erlangen, Germany
© Copyright 2025. All Rights Reserved by MedPath